On June 4, 2007, the Food and Drug Administration (FDA) announced a new advisory committee intended to counsel FDA on how to strengthen the communication of risks and benefits of FDA-regulated products to the public. The Risk Communication Advisory Committee will:
- Help FDA better understand the communication needs and priorities of the general public;
- Advise FDA on the development of strategic plans to communicate product risks and benefits; and
- Make recommendations to FDA on what current research suggests about crafting risk and benefit messages, as well as how to most effectively communicate specific product information to vulnerable audiences.